GlassScriptPhysician profile
Allison M Pagan
NPI 1295230068
$1,648.64
in general payments reported to CMS, 2019-2025
25 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.58 · 2022: $267 · 2023: $426 · 2024: $302 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $326.87 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $201.56 | 2021-2025 | |
| Abbvie INC. | $157.45 | 2023-2025 | |
| Novo Nordisk INC | $148.63 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $107.38 | 2023-2025 | Farxiga |
| Supernus Pharmaceuticals, INC. | $89.94 | 2024-2025 | Qelbree |
| Vertex Pharmaceuticals Incorporated | $79.86 | 2025 | |
| Astellas Pharma US INC | $56.47 | 2022-2024 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $52.62 | 2021-2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $52.45 | 2022 | |
| Pfizer INC. | $44.47 | 2022-2025 | |
| Inspire Medical Systems, INC. | $42.83 | 2025 | Inspire |
| Amgen INC. | $40.49 | 2022-2025 | Evenity, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.19 | 2025 | Caplyta |
| Viatris Specialty LLC | $32.89 | 2025 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $26.70 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.30 | 2022 | |
| Sumitomo Pharma America, INC. | $22.33 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $18.21 | 2022 | |
| Baxter Healthcare | $17.09 | 2023 | Hillrom - Life 2000 Ventilation System |
| Organon LLC | $15.53 | 2023 | Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2025 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $14.38 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $12.32 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Pagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.